Siham Abdelgani
The University of Texas Health Science Center at San Antonio(US)Texas Diabetes Institute(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Liver Disease Diagnosis and Treatment, Metabolism, Diabetes, and Cancer, Diabetes Management and Research
Most-Cited Works
- → Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )(2022)41 cited
- → Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes(2024)28 cited
- → Trimethoprim-sulfamethoxazole vs. colistin or ampicillin–sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study(2018)28 cited
- → Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients(2023)25 cited
- → Gastric and urinary bladder pressures correlate with intra-abdominal pressure in patients with morbid obesity(2021)11 cited
- → Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies(2022)8 cited
- → Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes(2021)7 cited
- → The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals(2023)6 cited
- → Vitamin A status in different stages of schistosomal cases and the effectiveness of oral vitamin A therapy(1990)6 cited
- → Plasma insulin is required for the increase in plasma angiopoietin‐like protein 8 in response to nutrient ingestion(2023)5 cited